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Objective: For decades, kidney cancer patients in Denmark have had lower survival than 
patients in the other Scandinavian countries. Our aim was to study possible changes in survival 
of patients with kidney cancer after implementation of two national Danish cancer plans.
Study design and setting: From 1998 through 2009 we included all patients (N = 2659) 
with an incident diagnosis of kidney cancer in two Danish regions (population 1.8 million). 
Data were retrieved from the Danish National Registry of Patients. We computed survival 
after 1, 3, and 5 years, stratified by age, and estimated mortality rate ratios (MRRs) using Cox 
regression to assess changes over time, controlling for age and gender. We lacked data on stage 
distribution. Among patients who had a nephrectomy we also computed 30-day mortality and 
30-day MRRs.
Results: During the study period, we identified 2659 patients with kidney cancer. The annual 
number of patients increased from 583 in the period 1998–2000 to 853 in the period 2007–2009. 
The median age at diagnosis was 69 years throughout the study period. The overall 1-year 
survival improved from 56% (1998–2000) to 63% (2007–2009), corresponding to an adjusted 
MRR of 0.78 (95% confidence interval [CI] 0.66–0.93). We predicted the 3-year survival to 
increase from 40% to 51% and the 5-year survival to increase from 33% to 42%, corresponding 
to predicted MRRs of 0.76 (95% CI 0.66–0.87) and 0.77 (95% CI 0.68–0.89), respectively. 
Survival increased in all age groups (15–59 years, 60–74 years, 75+ years) and in both genders, 
except for men below 60 years, for whom the 1-year survival declined from 76% to 69%. The 
30-day mortality after nephrectomy declined from 4% to 2% during the study period.
Conclusion: We observed an improvement in the survival and relative mortality in kidney 
cancer patients, although not in men younger than 60 years.
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Introduction
Kidney cancer is the third most common genitourinary cancer.1–3 In Europe, the 
  standardized incidence (to the World Health Organization world standard population) 
is 8.8 per 100,000, with a standardized incidence of 5.1 per 100,000 in women and 
10.5 per 100,000 in men.3 In Denmark, the number of new cases reported in 2009 
was 669; of these, 420 cases were seen in men and 249 in women.2
A study on survival of patients with kidney cancer in the Nordic countries in the 
period 1964–2003 found that throughout the study period kidney cancer patients 
in Denmark had the lowest 5-year relative survival ratios for both men and women 
compared with the other Scandinavian countries.4 For patients diagnosed between 
1999 and 2003, the relative survival was 40% (95% confidence interval [CI] 38–43) Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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for Danish women and 41% (95% CI 38–43) for Danish 
men, while survival in the other Nordic countries ranged 
between 52% and 62% for women and between 51% and 
69% for men.4
In 1998, Engeland et al published a study that compared 
relative survival of cancer patients between Denmark and 
the other Nordic countries and found that for cancers of the 
  stomach, colon, rectum, breast (female), and prostate the 
Danish patients had a markedly lower relative survival than 
the patients in the other countries.5 As a response to such 
poorer prognosis, the Danish National Board of Health 
launched the National Cancer Treatment Plans I and II 
in 2000 and 2005, focusing on improvement of cancer 
  treatment in Denmark.6 The Cancer Treatment Plans 
focused on   centralization of treatment, national clinical 
guidelines, shorter diagnostic delay, and establishment 
of multidisciplinary cancer teams. Hypothesizing that 
improvement of treatment of kidney cancer would lead to 
better survival and lower mortality from kidney cancer in 
Denmark, we used data from the population-based Danish 
National Registry of Patients (DNRP) from 1998 to 2009 
to examine potential changes in the survival of kidney 
cancer patients.
Material and methods
We conducted this study in the central and the northern 
  Denmark regions, with a combined population of 1.8   million. 
The study period was divided into the   following four 
  consecutive time periods: 1998–2000, 2001–2003, 
2004–2006, and 2007–2009. The National Health Service 
provides tax-supported health care for all inhabitants in 
Denmark, guaranteeing free access to hospitals. Virtually no 
kidney cancer patients were treated in private hospitals   
during the study period.
Identification of kidney cancer patients
Through the DNRP, we identified all patients who had a 
first-time hospitalization with kidney cancer in the period 
January 1, 1998 through December 31, 2009. The DNRP 
contains information about all admissions from nonpsychiatric 
hospitals in Denmark since 1977.7 Outpatient and emergency 
room visits at hospitals have been included since 1995. This 
registry includes information on civil registration number, 
dates of admission and discharge, surgical procedure(s) 
performed, and up to 20 diagnoses from each hospital contact. 
Diagnoses have been classified according to the International 
Classification of Diseases (ICD) 8th edition until the end of 
1993 and 10th edition (ICD-10) thereafter. The ICD-10 codes 
used to identify kidney cancer were DC 64.9 and DC 65.9. 
We used the DNPR to identify nephrectomy procedures 
(KAC.00 [nephrectomy], KAC.01 [percutaneous endoscopic 
nephrectomy], KAC.20 [nephroureterectomy], and KAC.21 
[percutaneous endoscopic nephroureterectomy]) conducted 
within 90 days of kidney cancer diagnosis.
Survival
Since 1968, the Central Office of Civil Registration has 
assigned a unique 10-digit personal identification   number 
to all Danish citizens.8 This number, unique to each 
  Danish   resident, is used in all Danish registries, allowing 
unambiguous individual-level data linkage. From the Civil 
Registration System we also obtained information on vital 
status (dead or alive), date of death, and residence for all 
cancer patients.
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Statistical analysis
We followed each patient from date of cancer diagnosis 
until emigration, death, or June 25, 2010, whichever came 
first. To visualize crude survival, we constructed Kaplan–
Meier curves stratified according to period of diagnosis 
(1998–2000, 2001–2003, 2004–2006, and 2007–2009). 
We estimated 1-, 3-, and 5-year survival. In the latter periods 
we estimated 3- and 5-year survival using a hybrid analysis in 
which we included the actual survival for as long as possible 
and then estimated the conditional probability of surviving 
thereafter based on the corresponding survival experience of 
patients in the previous period (ie, using a period analysis 
technique).9 To compare mortality over time we used Cox 
proportional hazards regression analysis with 1998–2000 as 
the reference period to estimate 1-, 3-, and 5-year mortality 
rate ratios (MRRs) and corresponding 95% CIs adjusting for 
age group (15–59 years, 60–74 years, $75 years) and gender. 
In separate models we included age as a continuous variable 
and as a cubic spline with three knots, respectively.
For the patients who underwent nephrectomy within 
90 days of kidney cancer diagnosis, we likewise computed 
30-day   mortality rates after surgery for the four time   periods. 
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Figure 2 Overall survival of Danish kidney cancer patients diagnosed in the period 1998–2009 in the central and the northern Denmark regions.
Table 1 One-, 3-, and 5-year crude cumulative survival and gender- and age-adjusted all-cause Mrrs in Danish kidney cancer patients, 
1998–2009
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 583 571 652 853
Median age (years) 69 69 69 68
1 year
Survival 56% (52%–60%) 60% (56%–64%) 62% (59%–66%) 63% (60%–67%)
Mrr 1(reference) 0.87 (0.73–1.04) 0.82 (0.69–0.98) 0.79 (0.67–0.94)
Adjusted Mrra 1(reference) 0.90 (0.75–1.07) 0.84 (0.70–1.00) 0.78 (0.66–0.93)
3 year
Survival 40% (36%–44%) 45% (41%–49%) 50% (47%–54%) 51% (47%–54%)b
Mrr 1(reference) 0.88 (0.75–1.02) 0.78 (0.67–0.91) 0.77 (0.66–0.88)b
Adjusted Mrra 1(reference) 0.90 (0.77–1.05) 0.78 (0.67–0.91) 0.76 (0.66–0.87)b
5 year
Survival 33% (29%–37%) 37% (33%–41%) 41% (38%–45%)b 42% (38%–45%)b
relative Mrr 1(reference) 0.89 (0.77–1.02) 0.80 (0.69–0.92)b 0.79 (0.69–0.90)b
Adjusted Mrra 1(reference) 0.91 (0.79–1.05) 0.80 (0.70–0.92)b 0.77 (0.68–0.89)b
Notes: The corresponding 95% confidence intervals are given in parentheses; aadjusted for age and gender; bpredicted values.
Abbreviation: Mrr, mortality rate ratio.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 2 One-, 3-, and 5-year survival and MRRs in Danish men with kidney cancer, 1998–2009, stratified by age group
Men 
Age (years)
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–59
  number of cancer patients 99 117 131 148
  1-year survival 76% (66%–83%) 72% (63%–79%) 78% (70%–84%) 69% (60%–76%)
  3-year survival 62% (51%–70%) 57% (48%–66%) 66% (57%–73%) 59% (50%–66%)a
  5-year survival 55% (44%–64%) 54% (44%–62%) 60% (51%–67%)a 53% (45%–61%)a
60–74
  number of cancer patients 136 137 159 226
  1-year survival 57% (48%–64%) 66% (57%–73%) 64% (56%–71%) 67% (60%–73%)
  3-year survival 45% (36%–53%) 48% (39%–56%) 55% (47%–63%) 54% (47%–61%)a
  5-year survival 35% (27%–43%) 35% (27%–43%) 42% (34%–50%)a 41% (34%–48%)a
75+
  number of cancer patients 100 86 102 138
  1-year survival 43% (33%–52%) 51% (40%–61%) 43% (33%–52%) 47% (38%–55%)
  3-year survival 26% (18%–35%) 36% (26%–46%) 31% (23%–40%) 36% (28%–45%)a
  5-year survival 18% (11%–26%) 26% (17%–35%) 22% (14%–30%)a 24% (17%–33%)a
Notes: The corresponding 95% confidence intervals are given in parentheses; apredicted values.
Abbreviation: Mrr, mortality rate ratio.
We used Cox proportional hazards regression analysis and 
  estimated 30-day MRRs with 1998–2000 as the reference period, 
adjusting for age group and gender. Analyses were   performed 
using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
A total of 2659 patients was diagnosed with kidney cancer in 
the period 1998–2009. Of these patients, 1579 were men and 
1080 were women. The annual number of patients diagnosed 
with kidney cancer increased from 583 in 1998–2000 to 
853 in 2007–2009. The median age at diagnosis was 69 years 
in the study period. The age distribution for each gender is 
shown in Figure 1. Overall, the survival improved over the 
study period (Figure 2); the 1-year survival improved from 
56% in 1998–2000 to 63% in 2007–2009, corresponding to 
an age and gender adjusted MRR of 0.78 (95% CI 0.66–0.93) 
(Table 1). It is expected that the 3-year survival will increase 
from 40% in 1998–2000 to 51% in 2007–2009, and the 5-year 
survival from 33% to 42%, corresponding to predicted age 
and gender adjusted MRRs of 0.76 (95% CI 0.66–0.87) and 
0.77 (95% CI 0.68–0.89) respectively (Table 1). Including 
age as either a continuous variable or as a spline in the model 
did not change these estimates.
Tables 2 and 3 show 1-, 3-, and 5-year survival for each 
gender, stratified by age. For women, an improvement in 
survival was observed throughout the study period. For men, 
an improvement was seen above the age of 60 years, whereas 
men younger than 60 years seemed not to have experienced 
the same improved survival.
From 1998 to 2009, the annual number of patients 
who received a nephrectomy within 90 days of kidney 
cancer diagnosis increased from 282 patients in 1998–2000 
(corresponding to 48.4% of patients diagnosed in this 
period) to 411 (48.2%) in 2007–2009. During the study 
period the 30-day mortality varied between 3.5% and 2.2%, 
corresponding to an age- and gender-adjusted 30-day MRR 
of 0.62 (95% CI 0.25–1.52) in 2007–2009 compared with 
1998–2000 (Table 4).
Discussion
In the study population of more than 2500 patients with 
kidney cancer, we observed an increase in the survival over 
the study period; although not for men below 60 years of age. 
At the same time, the annual number of patients diagnosed 
with kidney cancer also increased.
Our use of data collected through a uniformly organized 
health care system with free access for all patients allowed 
for a population-based design with complete follow-up. This 
minimizes the risk of referral and selection bias. Furthermore, 
although no validation studies of the coding of kidney cancer 
in the DNPR exists, a previous study comparing ovarian 
cancer data from the DNPR with data from the Danish 
Cancer Registry found a completeness of 96% and a positive 
predictive value of 87%.10 We have no reason to believe 
that the coding quality of kidney cancer is inferior to that of 
ovarian cancer, and thus, we do not expect misclassification 
of the kidney cancer diagnosis in the DNPR to have major 
impact on our estimates.Clinical Epidemiology 2011:3 (Suppl 1) submit your manuscript | www.dovepress.com
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Table 3 One-, 3-, and 5-year survival and MRRs in Danish women with kidney cancer, 1998–2009, stratified by age group
Women 
Age (years)
Year of diagnosis
1998–2000 2001–2003 2004–2006 2007–2009
15–59
  number of cancer patients 51 54 52 71
  1-year survival 75% (60%–84%) 72% (58%–82%) 65% (51%–77%) 77% (65%–85%)
  3-year survival 49% (35%–62%) 63% (49%–74%) 58% (43%–70%) 68% (54%–78%)a
  5-year survival 41% (28%–54%) 54% (40%–66%) 54% (40%–66%)a 63% (49%–74%)a
60–74
  number of cancer patients 116 108 118 146
  1-year survival 59% (49%–67%) 58% (48%–67%) 65% (56%–73%) 74% (66%–81%)
  3-year survival 41% (32%–50%) 39% (30%–48%) 52% (42%–60%) 58% (49%–66%)a
  5-year survival 34% (26%–43%) 32% (24%–41%) 44% (35%–52%)a 49% (40%–58%)a
75+
  number of cancer patients 81 69 90 124
  1-year survival 33% (23%–44%) 35% (24%–46%) 53% (43%–63%) 49% (40%–57%)
  3-year survival 19% (11%–28%) 26% (16%–37%) 36% (26%–45%) 33% (25%–41%)a
  5-year survival 12% (6%–20%) 20% (12%–30%) 25% (16%–34%)a 23% (16%–31%)a
Notes: The corresponding 95% confidence intervals are given in parentheses; apredicted values.
Abbreviation: Mrr, mortality rate ratio.
Table 4 Thirty-day mortality and Mrr after nephrectomy in Danish patients with kidney cancer, 1998–2009
Year of surgery
1998–2000 2001–2003 2004–2006 2007–2009
number of cancer patients 282 309 330 411
Median age (years) 67 66 64 65
30-day mortality 3.5% (1.9%–6.5%) 2.3% (1.1%–4.7%) 2.7% (1.4%–5.2%) 2.2% (1.1%–4.2%)
30-day Mrr 1(reference) 0.63 (0.24–1.66) 0.77 (0.31–1.89) 0.61 (0.25–1.51)
30-day Mrra 1(reference) 0.66 (0.25–1.72) 0.81 (0.33–1.99) 0.62 (0.25–1.52)
Notes: The corresponding 95% confidence intervals are given in parentheses; aadjusted for age and gender.
Abbreviation: Mrr, mortality rate ratio.
When interpreting our findings we also need to consider 
weaknesses of our study. Since we did not include informa-
tion about the general population in our region we could not 
compute incidence rates. We therefore could not confirm that 
the increase in the annual number of kidney cancer cases also 
reflected an increasing incidence of kidney cancer in northern 
Denmark. Another weakness was our lack of information on 
clinical characteristics such as cancer stage at diagnosis and 
cancer-directed treatment, other than nephrectomy. We were 
therefore unable to examine whether changes in stage or 
treatment could explain our findings of an improved survival. 
A previous study in patients diagnosed with rectal cancer 
in the Nordic countries and Scotland found that part of the 
differences in survival could be explained by differences in 
stage distribution between Denmark and the other countries.11 
Therefore, a high prevalence of advanced stage at diagnosis 
could be a possible explanation of the lower survival for 
  Danish kidney cancer patients. Because we lacked stage 
information, we could not compare the stage distribution with 
that of kidney cancer patients in other countries. Moreover, 
we could not examine whether our increasing annual num-
ber of kidney cancer patients was a result of increasing use 
of abdominal imaging giving rise to a higher proportion of 
early stage cancers and incidentalomas.12–15 If so, such tumors 
could be slow-growing lesions (not yet causing symptoms) 
with a better prognosis and thereby falsely improving the 
observed survival in the later study periods as compared 
with the early study period (length time bias). Another 
weakness is our lack of information regarding comorbidity 
and lifestyle factors, and we are therefore unable to examine 
whether changes in these factors may influence survival over 
time. A number of other factors may explain the improved 
survival observed in our study. Following the National Cancer 
Treatment Plans, a more aggressive diagnostic strategy has 
been implemented resulting in earlier diagnosis and thus an 
increased likelihood of curative treatment. If more patients 
are being diagnosed at an earlier stage in the most recent 
periods, they will be living longer with the kidney cancer Clinical Epidemiology
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diagnosis even without any improvements in time of death 
(lead-time bias). Improved surgical technique, extensive use 
of minimally invasive surgical procedures, and the introduc-
tion of new medical treatment modalities such as tyrosine 
kinase and mTOR (mammalian target of rapamycin) inhibi-
tors also have the potential to improve survival.16–18 However, 
several of these different initiatives have only recently been 
implemented, and therefore the full effect on overall cancer 
survival still remains to be seen.
Conclusion
In this 12-year period in northern Denmark we found an 
increasing annual number of kidney cancer patients. This 
increase was followed by a limited improvement in survival 
and relative mortality, although not in men younger than 
60 years.
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